Icon
Icon plc, headquartered in Ireland (IE), is a leading global provider of outsourced development and commercialisation services to the pharmaceutical, biotechnology, and medical device industries. Founded in 1990, Icon has established itself as a key player in the clinical research sector, with a strong presence across North America, Europe, and Asia. The company offers a comprehensive range of services, including clinical trial management, data analytics, and regulatory consulting, distinguished by its commitment to innovation and quality. Icon's unique approach integrates advanced technology and deep industry expertise, enabling clients to navigate the complexities of drug development efficiently. With a robust portfolio and a reputation for excellence, Icon plc has achieved significant milestones, including numerous successful product launches and partnerships with leading healthcare organisations, solidifying its position as a trusted partner in the life sciences industry.
DitchCarbon Score
How does Icon's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Icon's score of 55 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Icon's reported carbon emissions
In 2023, ICON plc reported total carbon emissions of approximately 44,770,000 kg CO2e, which includes 2,503,000 kg CO2e from Scope 1, 13,663,000 kg CO2e from Scope 2, and 28,605,000 kg CO2e from Scope 3 emissions. This marks an increase from 2022, where total emissions were about 41,137,000 kg CO2e. ICON has set ambitious climate commitments, aiming for net-zero greenhouse gas emissions across its value chain by FY2050. The company has established near-term targets to reduce absolute Scope 1 and 2 emissions by 61.2% by FY2028 from a FY2019 baseline, and to cut Scope 3 emissions by 20.0% by FY2028 from a FY2022 baseline. Long-term goals include a 90.0% reduction in both Scope 1 and 2 emissions by FY2050, as well as a 90.0% reduction in Scope 3 emissions by the same year. These targets align with the Science Based Targets initiative (SBTi) and reflect ICON's commitment to addressing climate change within the pharmaceuticals, biotechnology, and life sciences sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | 1,827,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 18,796,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 36,726,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Icon is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
